Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisionsHACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc.

<p><i><strong>Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions</strong></i></p><p><strong id="dateline">HACKENSACK, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 9, 2026 / </strong><strong>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CSBR">CSBR</a>)</strong>, a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.</p><p>The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies. Together, the data underscore Champions Oncology's focus on helping biopharma partners better understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.</p><p>Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy.</p><p>"At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier," said Rob Brainin, Chief Executive Officer of Champions Oncology. "By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance, and move forward with greater confidence."</p><p>Champions Oncology scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities.</p><p>For more information on Champions Oncology's presence at AACR 2026, including poster details and meeting opportunities, visit: <a rel="nofollow" href="https://pr.report/kjg7">https://www.championsoncology.com/meet-us-at-aacr-2026</a></p><p><strong>Contact Information</strong></p><p>Gavin Cooper<br/>Vice President, Global Marketing<br/>(518) 488-9062</p><p><strong>SOURCE: </strong>Champions Oncology, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-to-present-new-data-on-predicting-response-and-res-1156457'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1156457" width="0" height="0"/>

CSBR

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology to Showcase New Cancer Research Data at AACR 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisionsHACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Champions Oncology is set to present eight studies at the upcoming AACR 2026 meeting, emphasizing advancements in oncology drug development. This data could bolster partnerships with biopharma companies by enhancing decision-making in therapeutic responses, potentially positioning CSBR for greater market traction and investor interest.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Champions Oncology presents eight studies at AACR 2026.</li><li>Research includes areas like ovarian cancer and CAR-T therapies.</li><li>Data focuses on improving drug development decisions.</li><li>CEO emphasizes reducing translational risk and enhancing predictions.</li><li>Collaboration opportunities available with Champions Oncology&#039;s scientists.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Champions Oncology, Inc. (CSBR)</strong>: Focus on oncology research can strengthen its market position.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This falls under &#039;Industry News&#039; as it highlights new research developments critical for oncology stakeholders, fitting within the broader context of biopharma innovation paths.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Increased biopharma partnerships could enhance revenue visibility for CSBR.</li><li>Positive reception of research at AACR may drive stock price higher.</li><li>Possible announcements of collaborations post-event could further influence investor sentiment.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>CSBR will present at the AACR Annual Meeting from April 17-22, 2026.</li><li>Research areas include KRAS-mutant tumors and antibody-drug conjugates.</li><li>Studies aim to improve predictors of therapeutic response.</li><li>Rob Brainin highlighted the focus on reducing development risks.</li><li>Collaboration discussions will occur throughout the AACR event.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CSBR may see price appreciation in the short term due to upcoming AACR presentations.</p>
  </section>
</section>


<p><i><strong>Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions</strong></i></p><p><strong id="dateline">HACKENSACK, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 9, 2026 / </strong><strong>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CSBR">CSBR</a>)</strong>, a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.</p><p>The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies. Together, the data underscore Champions Oncology's focus on helping biopharma partners better understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.</p><p>Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy.</p><p>"At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier," said Rob Brainin, Chief Executive Officer of Champions Oncology. "By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance, and move forward with greater confidence."</p><p>Champions Oncology scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities.</p><p>For more information on Champions Oncology's presence at AACR 2026, including poster details and meeting opportunities, visit: <a rel="nofollow" href="https://pr.report/kjg7">https://www.championsoncology.com/meet-us-at-aacr-2026</a></p><p><strong>Contact Information</strong></p><p>Gavin Cooper<br/>Vice President, Global Marketing<br/>(518) 488-9062</p><p><strong>SOURCE: </strong>Champions Oncology, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-to-present-new-data-on-predicting-response-and-res-1156457'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1156457" width="0" height="0"/>

Champions Oncology is set to present eight studies at the upcoming AACR 2026 meeting, emphasizing advancements in oncology drug development. This data could bolster partnerships with biopharma companies by enhancing decision-making in therapeutic responses, potentially positioning CSBR for greater market traction and investor interest.

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News